INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22401, 14805, 'Rimexolone (ophthalmic)', 'Eye Infections', 'The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections.  Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection.  In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation.  In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents.  Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy.  If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22402, 29216, 'Rimexolone (ophthalmic)', 'Eye Infections', 'The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections.  Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection.  In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation.  In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents.  Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy.  If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22403, 14805, 'Rimexolone (ophthalmic)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children.  The equatorial and posterior subcapsular portions of the lens should be examined for changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22404, 29216, 'Rimexolone (ophthalmic)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children.  The equatorial and posterior subcapsular portions of the lens should be examined for changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22405, 4364, 'Rimegepant', 'Kidney Diseases', 'Rimegepant should be avoided in patients with ESRD as it not been studied in patients with CrCl less than 15 mL/min or among patients on dialysis.  No dosage adjustment is necessary for patients with mild to severe renal impairment.  A single-dose pharmacokinetic study showed exposure to rimegepant in patients with mild or severe renal impairment was not clinically meaningful different compared to normal subjects, however, exposure in subjects with moderate renal impairment was approximately 40% higher.  In healthy male subjects, 78% of a radiolabeled dose was excreted in the feces and 24% in the urine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22406, 4365, 'Rimegepant', 'Kidney Diseases', 'Rimegepant should be avoided in patients with ESRD as it not been studied in patients with CrCl less than 15 mL/min or among patients on dialysis.  No dosage adjustment is necessary for patients with mild to severe renal impairment.  A single-dose pharmacokinetic study showed exposure to rimegepant in patients with mild or severe renal impairment was not clinically meaningful different compared to normal subjects, however, exposure in subjects with moderate renal impairment was approximately 40% higher.  In healthy male subjects, 78% of a radiolabeled dose was excreted in the feces and 24% in the urine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22407, 4364, 'Rimegepant', 'Liver Failure', 'Rimegepant should be avoided in patients with severe hepatic impairment.  A dedicated pharmacokinetic study has shown an approximately 2-fold increased exposure to a single-dose of rimegepant in patients with severe hepatic impairment (Child-Pugh class C).  There were no clinically meaningful differences in rimegepant exposure with mild (Child-Pugh class A) and moderate hepatic impairment (Child-Pugh class B).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22408, 4365, 'Rimegepant', 'Liver Failure', 'Rimegepant should be avoided in patients with severe hepatic impairment.  A dedicated pharmacokinetic study has shown an approximately 2-fold increased exposure to a single-dose of rimegepant in patients with severe hepatic impairment (Child-Pugh class C).  There were no clinically meaningful differences in rimegepant exposure with mild (Child-Pugh class A) and moderate hepatic impairment (Child-Pugh class B).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22409, 9846, 'Riluzole', 'Alcoholism', 'Alcohol consumption may intensify the hepatotoxic potential of riluzole.  Therefore, patients should be warned to limit alcohol intake while receiving riluzole therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22410, 26109, 'Riluzole', 'Alcoholism', 'Alcohol consumption may intensify the hepatotoxic potential of riluzole.  Therefore, patients should be warned to limit alcohol intake while receiving riluzole therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22411, 9846, 'Riluzole', 'Liver Diseases', 'The use of riluzole has been frequently associated with an increase in liver enzymes between 3 and 5 times the upper limit of normal (ULN).  Therapy with riluzole should be administered cautiously in patients with a history of liver dysfunction.  Baseline liver function tests (LFTs) should be obtained in all patients.  Monitor patients for signs and symptoms of hepatic injury, every month for the first 3 months of treatment, and periodically thereafter.  The use of riluzole is not recommended if patients develop hepatic transaminases levels greater than 5 times the ULN.  Discontinue riluzole if there is evidence of liver dysfunction (e.g., elevated bilirubin).  Patients with mild or moderate [Child-Pugh score A and B] hepatic impairment had increases in AUC compared to patients with normal hepatic function, and may be at increased risk of adverse reactions.  The impact of severe hepatic impairment on riluzole exposure is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22412, 26109, 'Riluzole', 'Liver Diseases', 'The use of riluzole has been frequently associated with an increase in liver enzymes between 3 and 5 times the upper limit of normal (ULN).  Therapy with riluzole should be administered cautiously in patients with a history of liver dysfunction.  Baseline liver function tests (LFTs) should be obtained in all patients.  Monitor patients for signs and symptoms of hepatic injury, every month for the first 3 months of treatment, and periodically thereafter.  The use of riluzole is not recommended if patients develop hepatic transaminases levels greater than 5 times the ULN.  Discontinue riluzole if there is evidence of liver dysfunction (e.g., elevated bilirubin).  Patients with mild or moderate [Child-Pugh score A and B] hepatic impairment had increases in AUC compared to patients with normal hepatic function, and may be at increased risk of adverse reactions.  The impact of severe hepatic impairment on riluzole exposure is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22413, 9846, 'Riluzole', 'Neutropenia', 'The use of riluzole has rarely been associated with neutropenia with an absolute neutrophil count (ANC) less than 500/mm3.  The neutropenia developed within the first 2 months of treatment.  Therapy with riluzole should be administered cautiously in patients predisposed to neutropenia.  Patients should be warned to report any febrile illness.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22414, 26109, 'Riluzole', 'Neutropenia', 'The use of riluzole has rarely been associated with neutropenia with an absolute neutrophil count (ANC) less than 500/mm3.  The neutropenia developed within the first 2 months of treatment.  Therapy with riluzole should be administered cautiously in patients predisposed to neutropenia.  Patients should be warned to report any febrile illness.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22415, 9846, 'Riluzole', 'Kidney Diseases', 'Riluzole and its metabolites are eliminated via the kidney.  Therapy with riluzole should be administered cautiously in patients with renal dysfunction.  Reduced clearance and higher plasma levels may occur in these patients.  Women, native Japanese patients, and the elderly may metabolize or excrete riluzole at a slower rate.  The need for dosage adjustment is not known.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22416, 26109, 'Riluzole', 'Kidney Diseases', 'Riluzole and its metabolites are eliminated via the kidney.  Therapy with riluzole should be administered cautiously in patients with renal dysfunction.  Reduced clearance and higher plasma levels may occur in these patients.  Women, native Japanese patients, and the elderly may metabolize or excrete riluzole at a slower rate.  The need for dosage adjustment is not known.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22417, 0, 'Rifamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22418, 0, 'Rifamycin', 'Diarrhea', 'The use of rifamycin has not been demonstrated to be effective in the treatment of travelers'' diarrhea caused by pathogens other than E.  coli.  Treatment with this agent has not shown to be effective in patients with diarrhea complicated by fever and/or bloody stools.  Rifamycin is not recommended for use in patients with diarrhea accompanied by fever or bloody stools or due to pathogens other than noninvasive strains of E.  coli.  It is recommended to discontinue therapy if diarrhea gets worse or persists more than 48 hours and to consider alternative antibacterial therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22419, 0, 'Rifamycin', 'Liver Diseases', 'The pharmacokinetics of rifamycin in patients with impaired hepatic function have not been studied.  Rifamycin has limited systemic exposure after oral administration; therefore, it is not expected to necessitate a dose adjustment in patients with liver dysfunction.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22420, 0, 'Rifamycin', 'Kidney Diseases', 'The pharmacokinetics of rifamycin in patients with impaired renal function have not been studied.  Rifamycin has limited systemic exposure after oral administration and minor role of renal excretion in elimination of rifamycin; therefore, it is not expected to necessitate a dose adjustment in patients with impaired renal function.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22421, 30504, 'Risdiplam', 'Liver Diseases', 'The pharmacokinetics and safety of risdiplam in patients with severe hepatic impairment (Child-Pugh class C) have not been studied.  In patients with mild or moderate hepatic impairment, clinically meaningful differences have not been observed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22422, 0, 'Ripretinib', 'Heart Failure', 'Ripretinib may cause cardiac dysfunction.  The safety of ripretinib has not been assessed in patients with a baseline ejection fraction below 50%.  Assess ejection fraction by echocardiogram or multiple gated acquisition (MUGA) scan prior to initiating treatment with ripretinib and during treatment, as clinically indicated.  Permanently discontinue therapy for Grade 3 or 4 left ventricular systolic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22423, 0, 'Ripretinib', 'Hypertension', 'Ripretinib may cause hypertension.  It is recommended to control blood pressure prior to initiating therapy and monitor blood pressure as clinically indicated during treatment.  Based on severity, withhold treatment with ripretinib and resume at the same or reduced dose or permanently discontinue.  Do not initiate ripretinib in patients with uncontrolled hypertension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22424, 0, 'Ripretinib', 'Wounds and Injuries', 'Ripretinib has the potential to affect wound healing adversely.  Do not administer ripretinib for at least two weeks following major surgery and until adequate wound healing.  It is recommended to withhold ripretinib for at least one week before elective surgery.  Care should be exercised when using this agent in patients with impaired wound complications.  The safety of this agent after the resolution of wound healing complications has not been established.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22425, 4821, 'Risankizumab', 'Hepatic Insufficiency', 'No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22426, 31910, 'Risankizumab', 'Hepatic Insufficiency', 'No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22427, 4821, 'Risankizumab', 'Infections', 'Risankizumab may increase the risk of infections., and treatment with this medication should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.  In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing risankizumab.  Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur.  If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer risankizumab until the infection resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22428, 31910, 'Risankizumab', 'Infections', 'Risankizumab may increase the risk of infections., and treatment with this medication should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.  In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing risankizumab.  Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur.  If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer risankizumab until the infection resolves.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22429, 4821, 'Risankizumab', 'Tuberculosis', 'Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with risankizumab.  Consider anti-TB therapy prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.  Monitor patients for signs and symptoms of active TB during and after risankizumab treatment.  Do not administer this medication to patients with active TB.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22430, 31910, 'Risankizumab', 'Tuberculosis', 'Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with risankizumab.  Consider anti-TB therapy prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.  Monitor patients for signs and symptoms of active TB during and after risankizumab treatment.  Do not administer this medication to patients with active TB.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22431, 22166, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22432, 22167, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22433, 22168, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22434, 26189, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22435, 26190, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22436, 26219, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22437, 26223, 'Rituximab', 'Autoimmune Diseases', 'JC virus infection resulting in Progressive Multifocal Leukoencephalopathy (PML) and death can occur in rituximab-treated patients with hematologic malignancies or with autoimmune diseases.  Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations.  Discontinue rituximab and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22438, 22166, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22439, 22167, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22440, 22168, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22441, 26189, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22442, 26190, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22443, 26219, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22444, 26223, 'Rituximab', 'Heart Failure', 'Cardiotoxicity has been reported in a few patients receiving rituximab infusion during clinical studies.  Patients with a history of angina or arrhythmias have experienced recurrences of these conditions during administration of rituximab.  Therapy with rituximab should be administered cautiously in patients with preexisting arrhythmias or coronary artery or ischemic heart disease.  Clinical monitoring of cardiac function throughout infusion and immediately post-infusion is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22445, 22166, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22446, 22167, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22447, 22168, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22448, 26189, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22449, 26190, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22450, 26219, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22451, 26223, 'Rituximab', 'Hepatitis B', 'Rituximab, as other drugs classified as CD20-directed cytolytic antibodies can cause hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death.  Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive.  Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).  Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with rituximab.  Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following rituximab therapy.  In patients who develop reactivation of HBV while on rituximab, immediately discontinue rituximab and any concomitant chemotherapy, and institute appropriate treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22452, 22166, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22453, 22167, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22454, 22168, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22455, 26189, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22456, 26190, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22457, 26219, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22458, 26223, 'Rituximab', 'Tumor Lysis Syndrome', 'Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of rituximab in patients with Non-Hodgkin Lymphoma (NHL).  Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for Tumor Lysis Syndrome (TLS).  Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22459, 22166, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22460, 22167, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22461, 22168, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22462, 26189, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22463, 26190, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22464, 26219, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22465, 26223, 'Rituximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of rituximab.  Leukopenia and thrombocytopenia occur more frequently than anemia.  Severe myelosuppression has been reported rarely.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22466, 22166, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22467, 22167, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22468, 22168, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22469, 26189, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22470, 26190, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22471, 26219, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22472, 26223, 'Rituximab', 'Infections', 'Rituximab can cause serious, including fatal, bacterial, fungal, and new or reactivated viral infections during and following the completion of rituximab-based therapy.  Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).  New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C.  The manufacturer recommends discontinuing rituximab for serious infections and institute appropriate anti-infective therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22473, 22166, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22474, 22167, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22475, 22168, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22476, 26189, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22477, 26190, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22478, 26219, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22479, 26223, 'Rituximab', 'Kidney Diseases', 'Severe, including fatal, renal toxicity can occur after rituximab administration in patients with Non-Hodgkin''s Lymphoma (NHL).  Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials.  The combination of cisplatin and rituximab is not an approved treatment regimen.  Monitor closely for signs of renal failure and discontinue rituximab in patients with a rising serum creatinine or oliguria.  No formal studies have been conducted to examine the effects of renal impairment on the pharmacokinetics of rituximab.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22480, 22750, 'Rizatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22481, 26224, 'Rizatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22482, 22750, 'Rizatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22483, 26224, 'Rizatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22484, 22750, 'Rizatriptan', 'Liver Diseases', 'Rizatriptan is primarily metabolized by the liver.  Following oral administration in patients with alcoholic cirrhosis of the liver, the plasma concentrations of rizatriptan were not significantly altered in patients with mild hepatic impairment but were approximately 30% higher in patients with moderate hepatic impairment compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired hepatic function.  A lower initial dosage may be appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22485, 26224, 'Rizatriptan', 'Liver Diseases', 'Rizatriptan is primarily metabolized by the liver.  Following oral administration in patients with alcoholic cirrhosis of the liver, the plasma concentrations of rizatriptan were not significantly altered in patients with mild hepatic impairment but were approximately 30% higher in patients with moderate hepatic impairment compared to healthy controls.  Therapy with rizatriptan should be administered cautiously in patients with significantly impaired hepatic function.  A lower initial dosage may be appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22486, 22750, 'Rizatriptan', 'Migraine Disorders', 'The use of rizatriptan is contraindicated in patients with hemiplegic or basilar migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22487, 26224, 'Rizatriptan', 'Migraine Disorders', 'The use of rizatriptan is contraindicated in patients with hemiplegic or basilar migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22488, 22750, 'Rizatriptan', 'Phenylketonurias', 'Maxalt-MLT (brand of rizatriptan) orally disintegrating tablets contain 1.05 mg and 2.10 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22489, 26224, 'Rizatriptan', 'Phenylketonurias', 'Maxalt-MLT (brand of rizatriptan) orally disintegrating tablets contain 1.05 mg and 2.10 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22490, 22750, 'Rizatriptan', 'Kidney Diseases', 'Rizatriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment (CrCl = 10 to 60 mL/min/1.73 m2), the plasma concentrations of rizatriptan were not significantly altered compared to healthy controls.  In hemodialysis patients (CrCl < 2 mL/min/1.73 m2), however, the area under the plasma concentration-time curve (AUC) was approximately 44% greater than that in controls.  Therapy with rizatriptan should be administered cautiously in dialysis patients and patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22491, 26224, 'Rizatriptan', 'Kidney Diseases', 'Rizatriptan is excreted in the urine primarily as metabolites but also as unchanged drug.  Following oral administration in patients with renal impairment (CrCl = 10 to 60 mL/min/1.73 m2), the plasma concentrations of rizatriptan were not significantly altered compared to healthy controls.  In hemodialysis patients (CrCl < 2 mL/min/1.73 m2), however, the area under the plasma concentration-time curve (AUC) was approximately 44% greater than that in controls.  Therapy with rizatriptan should be administered cautiously in dialysis patients and patients with significantly impaired renal function.  A lower initial dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22492, 24890, 'Risedronic acid', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22493, 24890, 'Risedronic acid', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22494, 24890, 'Risedronic acid', 'Peptic Ulcer', 'Bisphosphonates may cause local irritation of the upper gastrointestinal mucosa.  Esophagitis and esophageal ulcers and erosions, occasionally with bleeding, as well as gastric and duodenal ulcers, have been reported, primarily with alendronate.  Because of their structural similarities, therapy with all bisphosphonates should be administered cautiously in patients with active upper gastrointestinal disorders.  The usual precautions should be followed closely to minimize the risk of irritation (i.e. taking the medication with a full glass of water after arising for the day and remaining upright for at least 30 minutes afterwards and until the first food intake of the day).  Therapy should be discontinued if dysphagia, odynophagia or retrosternal pain occurs.  The manufacturer of alendronate considers its use to be contraindicated in patients with abnormalities of the esophagus that may delay esophageal emptying, such as stricture or achalasia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22495, 24890, 'Risedronic acid', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22496, 24890, 'Risedronic acid', 'Kidney Diseases', 'Risedronate is primarily eliminated by the kidney.  The renal clearance of the drug is decreased in patients with impaired renal function.  Risedronate is not recommended for use in patients with creatinine clearance less than 30 mL/min due to a lack of clinical experience in this setting.  No dosage adjustment is necessary in patients with mild to moderate renal impairment (CrCl >= 30 mL/min).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22497, 9834, 'Rifampicin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22498, 9838, 'Rifampicin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22499, 9848, 'Rifampicin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22500, 26071, 'Rifampicin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
